Board of Directors - Scantox

Board of Directors

  1. Home
  2. About Scantox
  3. Board of Directors

Members of the Scantox Board of Directors are experts bringing strong knowledge and solid experience within the fields of science, leadership, entrepreneurship and private equity.

Jens Bager

Jens Bager

Your Title Goes Here

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

Read more

Since 2016, Jens has focused on non-executive directorships and has been Chairman of a number of companies including Ambu A/S and the Grundfos Foundation. He currently serves as Chairman for Better Collective A/S, Scantox A/S and Marleybones Ltd.

Nicolas Hooge

Nicholas Hooge

Your Title Goes Here

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

Read more

Nicholas joined Impilo in 2020 and is a member of Impilo’s investment committee. Nicholas graduated as Cand. Merc. Mat. From Copenhagen Business School in 2004. Prior to his employment at Impilo he was a Senior Director at EQT Partners where he worked from 2006-2019, based both in Copenhagen and New York with a focus on private equity and investments in infrastructure. From 2004-2006 Nicholas worked for Deutsche Bank in London focusing on M&A in the Nordic countries.

Daniel Spasic

Daniel Spasic

Your Title Goes Here

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

Read more

Daniel has more than 25 years in senior life science executive roles. In 1996 he joined Pharmacia & Upjohn in clinical drug development. He later moved on and founded TFS International, a global midsized clinical Contract Research Organization with $100+ million in revenues and serving 250 biopharma customers worldwide. Daniel is the recipient of numerous entrepreneurial achievement awards. His expertise covers biopharma- and healthcare services, medical devices, digital health and research technology-enabled services. He is currently serving as Executive Chairman in Trialbee, Board Chairman in Inhalation Sciences, Board NED in Proteros Biostructures, Board NED in NuvoAir and Board NED in Scantox. Daniel holds a technical degree in chemical engineering and an OPM from Harvard Business School. Daniel is based in Boston, USA.

Karsten Lindhardt

Karsten Lindhardt

Your Title Goes Here

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

Read more

20+ years in pharmaceutical industry, Co-founder, Director Scantox ApS, Head of R&D and CSO Egalet, senior positions in Novo Nordisk, Ferring, Prosidion & Curalogic.

Mette Kirstine Agger

Mette K. Agger

Your Title Goes Here

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

Read more

Senior Advisor and board member for numerous biopharmaceutical companies, where she utilizes her extensive industry experience as a strategic advisor. She currently serves on several boards, including Abzu, KLIFO, ScPharmaceuticals, D.O.F. and C. V Obel A/S.

Previously a managing partner of Lundbeckfonden Ventures, and later  Senior Advisor for Lundbeckfonden BioCapital (succeeding Lundbeckfonden Ventures). Earlier in her career, CEO and co-founder of 7TM Pharma A/S. Prior to this, she was part of the management team of NeuroSearch A/S.

Mette Kirstine Agger holds an M.Sc. in Biology and an MBA.

Impilo

Scantox is owned by the Nordic based investment company Impilo. Impilo is focused solely on investments in Nordic companies operating in the pharmaceutical, medical technology, healthcare services and other health-related industries. Their starting point is that their portfolio companies must contribute to a positive and sustainable development of the communities and markets in which they operate in order to remain successful in the long term.  Impilo invests in people’s opportunities to enjoy healthier lives in the future.